We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Newly Identified Biomarkers Detect Subcortical Small-vessel Disease

By LabMedica International staff writers
Posted on 04 Apr 2022

Biomarkers have been identified that were able to differentiate between classical Alzeheimer’s disease and subcortical small-vessel disease (SSVD), which is the most common vascular cognitive disorder. More...

Since no disease-specific cerebrospinal fluid (CSF) biomarkers are available for SSVD, the aim of investigators at the University of Gothenburg (Sweden) was to identify such markers.

For this study, the investigators worked with 170 healthy controls and patients from the Gothenburg Mild Cognitive Impairment (MCI) study who had been clinically diagnosed with SSVD dementia, Alzheimer's disease (AD), or mixed AD/SSVD. The investigators quantified CSF levels of amyloid-beta (Abeta)x-38, Abetax-40, Abetax-42, as well as soluble amyloid precursor protein (sAPP)-alpha and sAPP-beta.

Results revealed that sAPP-beta was lower in SSVD patients than in AD patients and controls. Receiver-operating characteristic (ROC) analyses showed that sAPP-beta moderately separated SSVD from AD and controls. Moreover, the CSF/serum albumin ratio was elevated exclusively in SSVD and could moderately separate SSVD from the other groups. These results showed that SSVD had a biomarker profile that differed from that of AD and controls, and to some extent also from mixed AD/SSVD, suggesting that signs of blood-brain barrier dysfunction and sAPP-beta could be additional tools to diagnose SSVD.

First author Dr. Petronella Kettunen, associate professor of neurobiology at the University of Gothenburg, said, “When we combined the biomarker for vascular injury with the protein fragment we identified, the potential for separating patients with subcortical small-vessel disease from control subjects, patients with Alzheimer’s disease, and patients with mixed dementia was improved. Up to now, we have had no markers for subcortical small-vessel disease, which means that the disease could not be easily identified by testing samples of spinal fluid or blood. We have now opened up an opportunity to identify the disease, enabling help for this patient group in the form of lifestyle changes and blood pressure-reducing medication.”

The SSVD study was published in the March 25, 2022, online edition of the journal Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring.

Related Links:
University of Gothenburg 

 


Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Urine Chemistry Control
Dropper Urine Chemistry Control
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Research has linked platelet aggregation in midlife blood samples to early brain markers of Alzheimer’s (Photo courtesy of Shutterstock)

Platelet Activity Blood Test in Middle Age Could Identify Early Alzheimer’s Risk

Early detection of Alzheimer’s disease remains one of the biggest unmet needs in neurology, particularly because the biological changes underlying the disorder begin decades before memory symptoms appear.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.